The MHRA has launched a new toolkit to better inform female patients about the risks of taking valproate medicines during pregnancy.
Taken by those with epilepsy and bipolar disorder, the treatment is associated with a risk of developmental disorders and birth defects in children if taken during pregnancy.
Welcoming the toolkit RPS English Pharmacy Board Chair Sandra Gidley said: “We welcome this new resource for patients. The Royal Pharmaceutical Society will be raising awareness of the toolkit with our members as well as providing them with our new support guidance. We will be urging pharmacists to use the toolkit as a way of facilitating conversations they have with patients about the risks of taking valproate medicines during pregnancy.”
Find more information on dispensing valproate for girls and women here.